Bayer Taps Deeper Into Beijing’s Biotech Potential, Renews Partnership With Tsinghua
This article was originally published in PharmAsia News
Executive Summary
Latest research deal for Bayer underscores Beijing’s growing importance as a biotech hub.
You may also be interested in...
Bayer Establishes Workspace For Start-Ups In An Innovative Move
One year after opening its Innovation Center in Mission Bay, Calif., Bayer is opening the space to start-ups to help establish their research labs.
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health